Immuno-Oncology | Specialty

Dr. Nghiem on Pembrolizumab for Advanced Merkel Cell Carcinoma

September 27th 2015

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine discusses a phase II trial investigating the PD-1 blockade pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma (MCC).

Nivolumab Before Ipilimumab Has Greater Efficacy, Similar AEs

September 27th 2015

Two strategies of sequential immunotherapy for advanced melanoma showed similar safety and tolerability but substantially different efficacy.

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

September 26th 2015

More than a fifth of patients with previously treated metastatic nasopharyngeal carcinoma showed a measurable response when treated with the immune checkpoint inhibitor pembrolizumab.

FDA Grants Nivolumab/Ipilimumab Combination Priority Review for Advanced Melanoma

September 26th 2015

The FDA has granted a priority review designation to a supplemental biologics license application for nivolumab plus ipilimumab in previously untreated patients with advanced melanoma.

Nivolumab Extends Survival in Advanced Renal Cell Carcinoma

September 25th 2015

Nivolumab reduced the risk of death by 27% versus everolimus in patients with advanced renal cell carcinoma, improving overall survival by 5.4 months.

Jeffrey Weber Joins NYU Langone, Plans to Expand Clinical Trial and Immunotherapy Initiatives

September 25th 2015

Immunotherapy expert Jeffrey Weber, MD, PhD, will join NYU Langone Medical Center's Laura and Isaac Perlmutter Cancer Center as its deputy director and co-director of its melanoma program.

Dr. James Allison's Big Year Continues With Lasker Award

September 23rd 2015

Immunotherapy pioneer James P. Allison, PhD, has been named the 2015 recipient of the Lasker-DeBakey Clinical Medical Research Award by the Albert and Mary Lasker Foundation.

Novel Immunotherapy Shows Promise in Metastatic Cervical Cancer

September 17th 2015

Tom Herzog, MD, discusses the vaccine ADXS11-001 (axalimogene filolisbac) in patients with persistent or recurrent metastatic cervical cancer.

Nivolumab Active in Platinum-Resistant Ovarian Cancer

September 17th 2015

Nivolumab (Opdivo) demonstrated clinical activity and safety in patients with platinum-resistant ovarian cancer.

FDA Grants Nivolumab Breakthrough Designation in Renal Cell Carcinoma

September 16th 2015

Nivolumab (Opdivo) has received an FDA breakthrough therapy designation for the treatment of patients with advanced renal cell carcinoma.

Dr. Carolyn Britten on Next Steps in Immunotherapy

September 15th 2015

Carolyn D. Britten, MD, chief, Division of Hematology Oncology, associate director, Clinical Investigations, at the Hollings Cancer Center, Medical University of South Carolina, discusses questions that remain in immunotherapy.

Nivolumab/Ipilimumab Combination Active in Advanced NSCLC

September 8th 2015

A chemotherapy-free regimen of nivolumab and ipilimumab demonstrated activity as a first-line therapy for patients with advanced non–small cell lung cancer.

Nivolumab Survival Benefit Sustained in Squamous NSCLC

September 8th 2015

Treatment with the PD-1 inhibitor nivolumab demonstrated a 32% reduction in the risk of death compared with docetaxel for patients with previously treated squamous non–small cell lung cancer.

Atezolizumab Plus Chemo Leads to High Response Rate in NSCLC

September 7th 2015

Patients with newly diagnosed metastatic non-small lung cancer had double the expected response when the PD-L1 inhibitor atezolizumab was added to chemotherapy.

Breast Cancer Pioneer Examines Novel Therapies for Metastatic Breast Cancer

September 3rd 2015

Dennis Slamon, MD, PhD, discusses the inhibition of CDK 4/6 and PD-1, which represent two of the most exciting developments in the field of metastatic breast cancer.

FDA Grants Nivolumab Priority Review in Nonsquamous NSCLC

September 2nd 2015

Nivolumab (Opdivo) has received an FDA priority review designation for patients with previously treated nonsquamous non–small cell lung cancer.

Dr. Zafar on the Potential of Immunotherapy in Colorectal Cancer

August 31st 2015

S. Yousuf Zafar, MD, associate professor of medicine, Duke Cancer Institute, discusses the potential of immunotherapy for the treatment of patients with colorectal cancer (CRC).

Combination Therapies Continue to Advance in Melanoma

August 31st 2015

Anna Pavlick, DO, discusses immunotherapy and targeted combination regimens in advanced melanoma.

Cancer Immunotherapy Meets Precision Medicine in Biomarker Study

August 29th 2015

Mismatch repair deficiency may serve as an immuno-oncology biomarker and may illustrate the clinical utility of analyzing the number of mutations per tumor.

FDA Grants Intravesical Immunotherapy Priority Review for Bladder Cancer

August 28th 2015

The FDA has assigned a priority review designation to the intravesical immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer following first-line bacillus Calmette-Guerin therapy.

NEXT PAGE
PREVIOUS PAGE
x